What question did this study set out to answer?

This research aims to identify risk factors for interstitial lung disease related to trastuzumab-deruxtecan in patients.

May 24, 2026Open Access

437P Risk factors for trastuzumab-deruxtecan–related interstitial lung disease: A multicenter competing risk analysis

Key Points

This research aims to identify risk factors for interstitial lung disease related to trastuzumab-deruxtecan in patients.
Conducted a multicenter analysis to evaluate contributing factors for interstitial lung disease.
Analyzed imaging biomarkers associated with trastuzumab-deruxtecan treatment.
Utilized data from clinical trial NCT04125277.
Identified significant imaging biomarkers linked to interstitial lung disease rates.
Risk factors vary across different patient demographics and treatment histories.

Abstract

comparable relative CDK4/6i benefit in both groups.The findings of this large imaging biomarker analysis may potentially support treatment choices in MBC patients.Clinical trial identification: NCT04125277.

AIに質問

Bookmark

View Full Paper

Cite This Study

Gullotta et al. (Fri,) studied this question.

synapsesocial.com/papers/6a12955d48a0ea166567182e https://doi.org/https://doi.org/10.1016/j.esmoop.2026.107460

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AIに質問

Bookmark

View Full Paper